Revlimid data presented at ASCO stands to change the way physicians treat multiple myeloma
Tampa, FL -- (June 4, 2007) -- Findings from a Phase III study by the Eastern Cooperative Oncology Group (ECOG 4A03) were presented yesterday at the American Society of Clinical Oncology (ASCO) meeting in Chicago and demonstrate the benefits of using Revlimid (lenalidomide) with reduced doses of the steroid dexamethasone. Based upon these data, the U.S. Myeloma Forum, a committee of leading mye...GlaxoSmithKline honors cancer research pioneer Gianni Bonadonna with new ASCO Award and Fellowship
CHICAGO June 1, 2007 GlaxoSmithKline Oncology (GSK), in support of The American Society of Clinical Oncology (ASCO) and The ASCO Foundation, proudly announce today the creation of the Gianni Bonadonna Breast Cancer Award and Fellowship as a tribute to Dr. Bonadonnas outstanding contributions in the field of cancer research. The annual Award and Fellowship will acknowledge clinical or translat...Pfizer Onocology press briefing scheduled during ASCO 2007 Annual Meeting
Featured speakers include:... ... Dr. Ezra Cohen, University of Chicago, Illinois USA... Dr. Ronald Bukowski, Cleveland Clinic Taussig Cancer Center, USA... Dr. Antoni Ribas, University of California, Los Angeles (UCLA), USA... Dr. Daniel D. Karp, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA... Dr. Craig Eagle, World Wide Medical Oncology, Pfizer... ... ... Opportu...Making science personal: Lilly Oncology to unveil 76 studies at ASCO 2007
... "This is an exciting time in cancer research as we are movi...Avantogen and Innovate announce ASCO abstracts
Avantogen Limited ("Avantogen", ASX:ACU), Sydney, Australia and San Diego, CA, and Innovate Oncology, Inc ("Innovate"; IOVO:OTCBB), New York, today announced that 2 abstracts reporting on the evaluation of the use of RP101 in the treatment of patients with pancreatic cancer, were published at this weeks American Society of Medical Oncology (ASCO) Meeting in Atlanta, Georgia.... ...The first abstr...New data at ASCO show CAMPTOSAR is key to treating 1st line metastatic colorectal cancer
ATLANTA, June 5 Data presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) demonstrated that CAMPTOSAR (irinotecan HCL injection), when given in the infusional regimen FOLFIRI , provided statistically significant longer progression free survival (PFS) compared to bolus mIFL and CapeIRI , two alternative chemotherapeutic regimens containing CAMPTOSAR used to t...PITT researcher honored at ASCO's Annual Meeting for new approach to lung cancer
ATLANTA University of Pittsburgh Cancer Institute (UPCI) researcher Suresh Ramalingam, M.D., received a Clinical Research Development Award from the American Society of Clinical Oncology (ASCO) for a study on a small molecule drug that appears to bolster the effect of chemotherapy for advanced non-small cell lung cancer patients. The award will be presented at ASCO's 42nd Annual Meeting in Atlant...ASCO and ESMO announce Consensus Statement on Quality Cancer Care
Atlanta, GA--The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), two of the world's leading oncology societies, today released a joint Consensus Statement on Quality Cancer Care for patients across the globe. The 10-point statement outlines goals to provide access to and continuity of quality cancer care worldwide and will be published jointly in...